Recent evidence suggests the potential for synergy with ICI, where tumours treated with CP-506 and combination immunotherapy of L19-IL2 and anti-PD-L1 delayed the growth of tumours and prolonged median survival. The gene discussed is IL2; the disease is neoplasm.